The Double Marker Test is a first-trimester prenatal screening test that helps assess the risk of chromosomal abnormalities in a developing fetus. It is particularly recommended for women over 35 years of age, those with a family history of genetic disorders, or those with abnormal ultrasound findings.

This test measures two crucial biomarkers in the mother’s blood:

Free Beta-hCG (Human Chorionic Gonadotropin): Abnormal levels may indicate an increased risk of Down syndrome (Trisomy 21).
PAPP-A (Pregnancy-Associated Plasma Protein-A): Lower levels can be associated with Edwards syndrome (Trisomy 18) and Patau syndrome (Trisomy 13).
The Double Marker Test is typically conducted between the 9th and 13th weeks of pregnancy and is often paired with an NT (Nuchal Translucency) scan for more accurate risk assessment. While this test does not provide a definitive diagnosis, abnormal results may indicate a higher risk and lead to further confirmatory tests like Amniocentesis or Chorionic Villus Sampling (CVS).

Early screening through the Double Marker Test helps in identifying potential genetic disorders, allowing expectant parents to make informed decisions about pregnancy care and necessary medical interventions.